MAMaureen V. Akinyi

Maureen V. Akinyi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maureen V. Akinyi has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Mikko J. Frilander

    Institute of Biotechnology, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland

    3 shared publications
  • Ali Oghabian

    Institute of Biotechnology Helsinki Institute of Life Science University of Helsinki Helsinki Finland

    1 shared publication
  • Antto J. Norppa

    Faculty of Science and Engineering Åbo Akademi University Turku Finland

    1 shared publication
  • Bas de Wolf

    Oncode Institute Hubrecht Institute - Royal Academy of Arts and Sciences and University Medical Centre Utrecht Utrecht The Netherlands

    1 shared publication
  • Berend Snel

    Theoretical Biology and Bioinformatics, Biology Science Faculty Utrecht University Utrecht The Netherlands

    1 shared publication
  • Bertrand Isidor

    Service de Génétique Médicale Unité de génétique Clinique CHU Hotel Dieu Nantes Cedex France

    1 shared publication

Latest Publications

  • Open Access

    Chromosomal instability by mutations in the novel minor spliceosome component CENATAC

    by Bas de Wolf, Ali Oghabian, Maureen V Akinyi, Sandra Hanks, Eelco C Tromer, Jolien J E van Hooff, Lisa van Voorthuijsen, Laura E van Rooijen, Jens Verbeeren, Esther C H Uijttewaal, et al.

    Aneuploidy is the leading cause of miscarriage and congenital birth defects, and a hallmark of cancer. Despite this strong association with human disease, the genetic causes of aneuploidy remain largely unknown. Through exome sequencing of patients with constitutional mosaic aneuploidy, we identified biallelic truncating mutations in CENATAC ( CCDC84 ). We show that CENATAC is a novel component of the minor (U12‐dependent) spliceosome that promotes splicing of a specific, rare minor intron subtype. This subtype is characterized by AT‐AN splice sites and relatively high basal levels of intron retention. CENATAC depletion or expression of disease mutants resulted in excessive retention of AT‐AN minor introns in ˜ 100 genes enriched for nucleocytoplasmic transport and cell cycle regulators, and caused chromosome segregation errors. Our findings reveal selectivity in minor intron splicing and suggest a link between minor spliceosome defects and constitutional aneuploidy in humans.


  • Open Access

    Minor spliceosome and disease

    by Bhupendra Verma, Maureen V. Akinyi, Antto J. Norppa, Mikko J. Frilander


  • Open Access

    The emerging role of minor intron splicing in neurological disorders

    by Daniel Jutzi, Maureen V. Akinyi, Jonas Mechtersheimer, Mikko J. Frilander, Marc-David Ruepp

    The emerging role of minor intron splicing in neurological disorders –


  • Open Access

    TDP-43 affects splicing profiles and isoform production of genes involved in the apoptotic and mitotic cellular pathways

    by Laura De Conti, Maureen V. Akinyi, Ramiro Mendoza-Maldonado, Maurizio Romano, Marco Baralle, Emanuele Buratti

    In recent times, high-throughput screening analyses have broadly defined the RNA cellular targets of TDP-43, a nuclear factor involved in neurodegeneration. A common outcome of all these studies is that changing the expression levels of this protein can alter the expression of several hundred RNAs within cells. What still remains to be clarified is which changes represent direct cellular targets of TDP-43 or just secondary variations due to the general role played by this protein in RNA metabolism. Using an HTS-based splicing junction analysis we identified at least six bona fide splicing events that are consistent with being controlled by TDP-43. Validation of the data, both in neuronal and non-neuronal cell lines demonstrated that TDP-43 substantially alters the levels of isoform expression in four genes potentially important for neuropathology: MADD/IG20, STAG2, FNIP1 and BRD8. For MADD/IG20 and STAG2, these changes could also be confirmed at the protein level. These alterations were also observed in a cellular model that successfully mimics TDP-43 loss of function effects following its aggregation. Most importantly, our study demonstrates that cell cycle alterations induced by TDP-43 knockdown can be recovered by restoring the STAG2, an important component of the cohesin complex, normal splicing profile.